Cutia Therapeutics (HKG:2487) posted a loss attributable to owners of 340.2 million yuan for 2025, narrowing from a loss of 433.8 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.
Loss per share at the pharmaceutical company came in at 1.03 yuan, compared with 1.41 yuan a year earlier.
Revenue rose to 336.2 million yuan from 279.6 million yuan in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.